Investing in Psychedelic Startups and the Decision to Move to For-Profit Funding

The speaker and others are heavily invested in psychedelic startups and are focused on therapeutics. They believe in revolutionizing capitalism by funding initiatives that for-profits aren't interested in or that are better suited for non-profits. Initially, there was very little for-profit activity in the psychedelics space, but recently, a subsidiary drug company of Maps raised $100 million in an equity financing round, prompting Maps to consider moving to for-profit funding. The decision was influenced by the need for more funding to deliver treatments, the desire to redeploy philanthropic capital to other initiatives, and the potential to attract more pharmaceutical companies into the space. The speaker believes that creating an investable ecosystem for psychedelics is important within the current capitalist system.